Targeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemia.
Bulgar
A D
AD
Snell
M
M
Donze
J R
JR
Kirkland
E B
EB
Li
L
L
Yang
S
S
Xu
Y
Y
Gerson
S L
SL
Liu
L
L
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000037:antagonists & inhibitors; D004249:DNA Damage / Q000187:drug effects; D004260:DNA Repair / Q000187:drug effects*; D004357:Drug Synergism; D006801:Humans; D006898:Hydroxylamines / Q000494:pharmacology*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured; D051981:Uracil-DNA Glycosidase / Q000378:metabolism; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D006898:Hydroxylamines; D012333:RNA, Messenger; C005214:methoxyamine; D004248:DNA (Cytosine-5-)-Methyltransferases; D051981:Uracil-DNA Glycosidase; D014740:Vidarabine; C024352:fludarabine